171 related articles for article (PubMed ID: 25770775)
1. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.
Mukker JK; Singh RS; Derendorf H
Adv Drug Deliv Rev; 2015 May; 85():57-64. PubMed ID: 25770775
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs.
Matera MG; Calzetta L; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Deliv; 2021 Jul; 18(7):891-906. PubMed ID: 33412922
[No Abstract] [Full Text] [Related]
3. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
Preston SL
Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
[TBL] [Abstract][Full Text] [Related]
4. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
Andes D; Anon J; Jacobs MR; Craig WA
Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
[TBL] [Abstract][Full Text] [Related]
5. Delivery of antibiotics to the respiratory tract: an update.
Traini D; Young PM
Expert Opin Drug Deliv; 2009 Sep; 6(9):897-905. PubMed ID: 19637984
[TBL] [Abstract][Full Text] [Related]
6. Challenges in inhaled product development and opportunities for open innovation.
Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
[TBL] [Abstract][Full Text] [Related]
7. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
McKellar QA; Sanchez Bruni SF; Jones DG
J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model.
Raut A; Dhapare S; Venitz J; Sakagami M
Biopharm Drug Dispos; 2020 Feb; 41(1-2):32-43. PubMed ID: 31691979
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Tasso L; de Andrade C; Dalla Costa T
Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions.
Caniga M; Cabal A; Mehta K; Ross DS; Gil MA; Woodhouse JD; Eckman J; Naber JR; Callahan MK; Goncalves L; Hill SE; Mcleod RL; McIntosh F; Freke MC; Visser SA; Johnson N; Salmon M; Cicmil M
J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):362-77. PubMed ID: 26859446
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies.
d'Angelo I; Conte C; La Rotonda MI; Miro A; Quaglia F; Ungaro F
Adv Drug Deliv Rev; 2014 Aug; 75():92-111. PubMed ID: 24842473
[TBL] [Abstract][Full Text] [Related]
14. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
15. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
Fish DN; Kiser TH
Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of inhaled antimicrobials.
Stockmann C; Roberts JK; Yellepeddi VK; Sherwin CM
Clin Pharmacokinet; 2015 May; 54(5):473-92. PubMed ID: 25735634
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.
Wu B; Derendorf H
Pharmazie; 2010 Jun; 65(6):417-20. PubMed ID: 20614689
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
[TBL] [Abstract][Full Text] [Related]
20. Duration of antibiotic treatment in surgical infections of the abdomen. Pharmacokinetic basis for short courses of antimicrobial therapy.
Wittmann DH
Eur J Surg Suppl; 1996; (576):19-23. PubMed ID: 8908464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
